<DOC>
	<DOC>NCT00314912</DOC>
	<brief_summary>The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimerâ€™s disease.</brief_summary>
	<brief_title>Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description>Duration of treatment: 12 months. Patients who complete the Phase III clinical trial will be offered the opportunity to receive Tramiprosate (3APS) in an open-label extension study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Tramiprosate</mesh_term>
	<criteria>The patient must have successfully completed the full 78week duration of the doubleblind CL758007 study. Male or female (age 50 years and older): Female must be of nonchildbearing potential (i.e. surgically sterilized or at least 2 years postmenopausal). Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver. The patient must be presenting a reasonably good nutritional status. Signed inform consent from the patient or legal representative. Patients will not be eligible to participate in the study if they meet any of the following criteria: The patient participates in another drug trial during the study. The patient with a clinically significant and/or uncontrolled condition or other significant medical disease. The patient is unable to swallow medication tablets.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>